Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28061038 | 0.86 | STAT3 (0.63) | STAT3HSD17B10CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3396574 | 0.81 | STAT3 (0.74) | STAT3HSD17B10POLBGFERCYP1A2 | |
| SCHEMBL4493312 | 0.81 | KDM4E (0.56) | HSD17B10POLBCYP1A2CYP3A4MAPT | |
| SCHEMBL4388703 | 0.77 | PKM (0.50) | STAT3HSD17B10POLBGFERMAPT | |
| SCHEMBL28519310 | 0.76 | STAT3 (0.58) | STAT3HSD17B10MAPT | |
| SCHEMBL11382070 | 0.74 | STAT3 (0.58) | STAT3HSD17B10POLBGFERCYP1A2 | |
| SCHEMBL30897295 | 0.74 | STAT3 (0.58) | STAT3HSD17B10POLBGFERCYP1A2 | |
| SCHEMBL584367 | 0.74 | PKM (0.73) | CYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL29466101 | 0.74 | PKM (0.73) | CYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL24273653 | 0.73 | CYP1A2 (0.79) | STAT3POLBCYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2800748-B1 | CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2017-03-29 | — | — | EP | disclosed |
| US-9453014-B2 | Cyclic amide derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase and uses thereof | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2016-09-27 | — | — | US | disclosed |
| US-9453014-B2 | Cyclic amide derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase and uses thereof | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2016-09-27 | — | — | US | disclosed |
| US-20150158860-A1 | CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2015-06-11 | — | — | US | disclosed |
| US-20150158860-A1 | CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2015-06-11 | — | — | US | disclosed |
| US-8772509-B2 | Indole compounds as positive allosteric modulators of the muscarinic receptor | VANDERBILT UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772509-B2 | Indole compounds as positive allosteric modulators of the muscarinic receptor | VANDERBILT UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2013128465-A1 | CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2013-09-06 | — | — | WO | disclosed |
| US-20130210773-A1 | INDOLE COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC RECEPTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-15 | — | — | US | disclosed |
| US-20130210773-A1 | INDOLE COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC RECEPTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-15 | — | — | US | disclosed |
| WO-2011163280-A1 | INDOLE COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC RECEPTOR | VANDERBILT UNIVERSITY (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011163280-A1 | INDOLE COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC RECEPTOR | VANDERBILT UNIVERSITY (US) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158860-A1 | CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF | HSD11B1, HSD11B2, HSD17B1 | STAT3 4106/4885HSD17B10 10/4885POLB 1907/4885 |
| US-20130210773-A1 | INDOLE COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC RECEPTOR | CHRM1, CHRM5, CHRM2 | STAT3 3056/4885HSD17B10 3906/4885POLB 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.